Cite
HARVARD Citation
Blumendeller, C. et al. (2021). Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report. Journal for immunotherapy of cancer. 9 (1), p. . [Online].